Projects per year
Personal profile
Biography
Dr Rudd specialises in mass spectrometry imaging, with specific expertise in drug mapping, spatial metabolomics and nanomaterial enabled imaging techniques.
Part-time, Dr Rudd is the MALDI-MS technical specialist at the HMSTrust Analytical Laboratory, Monash Institute of Pharmaceutical Sciences - assisting in experimental design, analysis and data interpretation to both academia and commercial/pharmaceutical clients (by collaboration and fee-for-service).
Dr Rudd is also a research fellow residing at the Melbourne Centre for Nanofabrication, where he uses novel nano-fabrication strategies to design rapid and confirmatory analytical tests for drug detection, biomarker analysis, biochemical profiling and contaminant detection. The main drive of his research program is to enable high through-put and cost effective analytical platforms that can transform drug testing processes.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
-
SDG 14 Life Below Water
Collaborations and top research areas from the last five years
-
Dissecting chronic pain in Epidermolysis Bullosa to identify new analgesic targets
Veldhuis, N. (Primary Chief Investigator (PCI)), Kern, J. (Chief Investigator (CI)), Rudd, D. (Chief Investigator (CI)), Nyström, A. (Chief Investigator (CI)), Pattison, L. (Chief Investigator (CI)), Poole, D. (Associate Investigator (AI)), Nowell, C. (Associate Investigator (AI)), Siddiqui, G. (Associate Investigator (AI)) & Akbarzadeh, S. (Associate Investigator (AI))
1/01/26 → 31/12/29
Project: Research
-
On-Site, Reponsive and Less Invasive Drug Testing In Correctional Services
Rudd, D. (Primary Chief Investigator (PCI))
ARC - Australian Research Council, Department of Corrective Services NSW
29/08/24 → 28/08/28
Project: Research
-
High-Precision Mass Spectrometry Imaging Facility
Voelcker, N. (Primary Chief Investigator (PCI)), Tuck, K. (Chief Investigator (CI)), McConville, M. J. (Chief Investigator (CI)), Li, J. (Chief Investigator (CI)), Loessner, D. (Chief Investigator (CI)), Pigram, P. (Chief Investigator (CI)), van Oppen, M. J. H. (Chief Investigator (CI)), Winkler, D. (Chief Investigator (CI)), Hartland, E. (Partner Investigator (PI)), Velkov, T. (Chief Investigator (CI)), Stewart, A. (Chief Investigator (CI)), Schittenhelm, R. (Partner Investigator (PI)), Williamson, N. A. (Chief Investigator (CI)), Rudd, D. (Partner Investigator (PI)) & Pham, K. N. (Partner Investigator (PI))
ARC - Australian Research Council
17/03/23 → 31/12/23
Project: Research
-
Revealing the mechanisms of chronic pain in dystrophic EB
Veldhuis, N. (Primary Chief Investigator (PCI)), Pang, K. (Chief Investigator (CI)), Nyström, A. (Chief Investigator (CI)), Kern, J. (Chief Investigator (CI)), Robertson, S. J. (Chief Investigator (CI)), Edgington-Mitchell, L. (Associate Investigator (AI)), Rudd, D. (Associate Investigator (AI)) & Nowell, C. (Associate Investigator (AI))
18/08/21 → 17/08/24
Project: Research
-
Evaluation of Non-Invasive Drug Detection Methods
Rudd, D. (Primary Chief Investigator (PCI))
Department of Communities and Justice (New South Wales)
27/09/18 → 27/09/19
Project: Research
-
Gold Nanoclusters as Smart Nanoplatforms for Targeted Cancer Therapy
Farkhani, S. M., Rudd, D., Thissen, H., Ali, M. A., Yuce, M., Cifuentes-Rius, A. & Voelcker, N. H., Oct 2025, In: Advanced NanoBiomed Research. 5, 10, 16 p., 2500037.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model
Derseh, H. B., Davies, A. N., Young, A., Bischof, S., Pelle, J., Rudd, D., McIntosh, M., Piedrafita, D. & Bischof, R. J., 5 Aug 2025, In: BMC Pulmonary Medicine. 25, 1, 11 p., 374.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Triple-Negative Breast Cancer Aptamer-Targeting Porous Silicon Nanocarrier
Malhotra, A., Dehghankelishadi, P., Kaur, I., Marshall, M., Rudd, D., Wojnilowicz, M., Nowell, C. J., Fulcher, A. J., Esser, L., Tong, W. Y., Cifuentes, A., Wagstaff, K. M. & Voelcker, N. H., 29 Jan 2025, In: ACS Applied Materials & Interfaces. 17, 4, p. 5955-5969 15 p.Research output: Contribution to journal › Article › Research › peer-review
8 Link opens in a new tab Citations (Scopus) -
Cardiac-targeted delivery of a novel Drp1 inhibitor for acute cardioprotection
Lees, J. G., Greening, D. W., Rudd, D. A., Cross, J., Rosdah, A. A., Lai, X., Lin, T. W., Phang, R. J., Kong, A. M., Deng, Y., Crawford, S., Holien, J. K., Hausenloy, D. J., Shen, H. H. & Lim, S. Y., Sept 2024, In: Journal of Molecular and Cellular Cardiology Plus. 9, 14 p., 100085.Research output: Contribution to journal › Article › Research › peer-review
Open Access12 Link opens in a new tab Citations (Scopus) -
Porous Silicon Microparticles Enable Sustained Release of GLP-1R Agonist Peptides for the Treatment of Type 2 Diabetes
Zangabad, P. S., Vasani, R. B., Tong, Z., Anderson, D., Rudd, D., Hick, C. A., Wootten, D., Sexton, P. M., Yan, L., Esser, L. & Voelcker, N. H., Dec 2024, In: Advanced Therapeutics. 7, 12, 18 p., 2400136.Research output: Contribution to journal › Article › Research › peer-review
Open Access8 Link opens in a new tab Citations (Scopus)
Equipment
-
HMSTrust Analytical Laboratory (HMST)
Rudd, D. (Manager) & McIntosh, M. (Other)
Drug Delivery Disposition & DynamicsFacility/equipment: Facility